Jessica J. Lin, Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson, Benjamin Besse, D. Ross Camidge, Toshio Fujino, Satoshi Yoda, et al. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discovery. 2024
Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, et al. Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023
Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, et al. Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing. JTO clinical and research reports. 2023. 4. 9. 100554-100554
Sun Min Lim, Toshio Fujino, Chulwon Kim, Gwanghee Lee, Yong-Hee Lee, Dong-Wan Kim, Jin Seok Ahn, Tetsuya Mitsudomi, Taiguang Jin, Sang-Yoon Lee. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023. 29. 16. 3004-3016
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. Journal of hematology & oncology. 2022. 15. 1. 79-79
PROGRESS IN MEDCINE
ライフ・サイエンス 2018 ISBN:9784898016374
検診胸部X線写真の読影
国際医学出版 2016 ISBN:4861022630
講演・口頭発表等 (8件)：
Preclinical Activity of NVL-655 in Patient-Derived Models of ALK Cancers, Including Those with Lorlatinib-Resistant G1202R/L1196M Compound Mutation
(EORTC-NCI-AACR 2022 2022)
Proposal of foretinib as second-line TKI after capmatinib/tepotinib treatment failure in NSCLC with MET exon14 mutation.
(IASLC 2022 World Conference on Lung Cancer 2022)
Treatment strategy of lung cancer with MET, NTRK and BRAF gene aberrations: Insights from in vitro and clinical data
(第19回日本臨床腫瘍学会学術集会 2022)
Comprehensive analysis of secondary mutation as resistance mechanism to seven MET-TKIs for MET exon 14 skipping in vitro
(20th World Conference on Lung Cancer 2019)
In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping
(19th World Conference on Lung Cancer 2018)
